Pancreatic Cancer News & Features
Pancreatic cancer may potentially be safely and effectively treated with immunochemotherapy, according to recent research from a preclinical study.
Olaparib, an experimental oral cancer drug, has shown an overall tumor response rate of 26% in advanced cancers associated with BRCA1 and BRCA2 mutations, according to recent research.
Increased expression of a microRNA (miRNA) panel seems highly accurate for diagnosis of pancreatic ductal adenocarcinoma (PDAC), according to a study published online.
New research that provides a better understanding of pancreatic cancer may help identify those people at increased risk.
Patients with a family history of pancreatic cancer may be at an increased risk for developing the disease.
- Ovarian cancer patients may benefit from pelvic radiotherapy
- Added sugars may increase blood pressure more than high salt consumption
- Researchers identify biological indicator of response to new ovarian cancer drug
- Key discovery in understanding successes and failures of immunotherapy
- Evolving roles for oncology nurses: Biospecimen collection
- Rociletinib produces response in treatment-resistant advanced non-small cell lung cancer (NSCLC)
- Utilizing home therapy for cancer-related lymphedema can lower costs
- Drug combination produces good response rates in advanced papillary renal cell carcinoma (pRCC)
- Breast cancer and pregnancy: Overlapping of two disciplines
- IDH1 mutation inhibitor first to demonstrate anticancer activity
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|